Skip to main content

Table 1 Primers used in the study

From: Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

Genes Sequences (5′-3′)
BCL-2 F: TGTGTGTGGAGAGCGTCAAC
R: GACAGCCAGGAGAAATCAAAC
GAPDH F: AGCCACATCGCTCAGACAC
R: GCCCAATACGACCAAATCC
IL6 F: TACCCCCAGGAGAAGATTCC
R: TTTTCTGCCAGTGCCTCTTT
IL-8 F: CTGGACCCCAAGGAAAACTG
R: TTCTCAGCCCTCTTCAAAAAC
SVV F: GAACTGGCCCTTCTTGGAG
R: AAGTCTGGCTCGTTCTCAGTG
TGFβ1 F: TGCTAATGGTGGAAACCCACAACG
R: TCTCGGAGCTCTGATGTGTTGAAG
TNFA F: CTCCTCACCCACACCATCAG
R: GGAAGACCCCTCCCAGATAG
VEGF F: GTGATGATTCTGCCCTCCTC
R: CCTTGCTGCTCTACCTCCAC
  1. BCL-2 B-cell lymphoma 2, GAPDH glyceraldehyde 3-phosphate dehydrogenase, IL6 interleukin 6, IL8 interleukin 8, SVV survivin, TGFβ1 transforming growth factor β1, TNFA tumor necrosis factor α, VEGF vascular endothelial growth factor